U-M clinical trial to target breast cancer stem cells now enrolling patients
Laboratory research that has illuminated the behavior of cancer stem cells, led by Taubman Scholar Dr. Max Wicha, founding director of the University of Michigan's Comprehensive Cancer Center, is being translated into a human clinical trial of the drug reparixin. Reparixin used in mice with breast cancer has shown promise in controlling cancer stem cells and metastasis.
Here's an excerpt from the University of Michigan press release on the trial, which is now accepting applications from prospective subjects:
A major reason that breast cancer returns after treatment and spreads to other parts of the body is that current chemotherapy and radiation treatments do not kill the cancer stem cells.
That premise provides the basis for a clinical trial open at the University of Michigan Comprehensive Cancer Center and two other sites testing a drug that has been found in laboratory studies to attack cancer stem cells. The drug, reparixin, will be used in combination with standard chemotherapy.
“This is one of only a few trials testing stem cell directed therapies in combination with chemotherapy in breast cancer. Combining chemotherapy with stem cell therapy has the potential to lengthen remissions for women with advanced breast cancer,” says principal investigator Anne Schott, M.D., associate professor of internal medicine at the University of Michigan.
Cancer stem cells are the small number of cells within a tumor that fuel its growth and spread.
The phase Ib study will test reparixin, which is taken orally, along with the chemotherapy drug paclitaxel in women with HER2-negative metastatic breast cancer. The study is primarily intended to test how patients tolerate this drug combination, but researchers will also look at how reparixin appears to be impacting markers for cancer stem cells and signs of inflammation. The study will also look at how effective this treatment combination is at controlling the cancer and impacting survival.
The clinical trial stems from researc at U-M that identified a receptor called CXCR1 on the cancer stem cells that triggers growth of stem cells in response to inflammation and tissue damage. Adding reparixin to chemotherapy in laboratory studies specifically targeted and killed breast cancer stem cells by blocking CXCR1.
Mice treated with reparixin or the combination of reparixin and chemotherapy had dramatically fewer cancer stem cells than those treated with chemotherapy alone. In addition, reparixin-treated mice developed significantly fewer metastases than mice treated with chemotherapy alone.
The study is sponsored by Dompé S.p.A. For more information about this trial, “Phase Ib pilot study to evaluate reparixin in combination with chemotherapy with weekly paclitaxel in patients with HER-2 negative metastatic breast cancer (MBC),” call the U-M Cancer AnswerLine at 800-865-1125.
Taubman-sponsored research offers breast tumor insights
Taubman Emerging Scholar Dr. Scott Tomlins has authored a new study about phyllodes tumors.
New U-M President visits Taubman Institute
The Institute hosted a fellow clinician-scientist when the University of Michigan’s new president paid a visit to the A. Alfred Taubman Biomedical Science Research Building.
Familial ALS affects generations
Detroit News column featuring Dr. Eva Feldman depicts the toll of the disease on one Metro Detroit family
news & events
In the News
Taubman Emerging Scholar makes strides against cancer
Erika Newman, M.D., has identified a characteristic of deadly childhood neuroblastoma that may pave the way for more effective treatments.
Drug cuts risk of bone-marrow transplant side effect
Taubman Emerging Scholar Sung Won Choi, M.D., is the lead author of a new study that finds a new way to help prevent graft-vs-host disease in cancer patients receiving bone-marrow transplants.
Study: Two types of cancer stem cells lead to metastasis
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to a new study published by Taubman Senior Scholar Dr. Max Wicha.